SECTOR:

Oncology

FUND/VEHICLE:

Pivotal US

INVESTMENT DATE:

2019

GEOGRAPHY:

North America

STATUS CURRENT/FORMER INVESTMENT:

Existing

WEBSITE:

A clinical stage biopharmaceutical company with the goal of curing cancer by developing targeted alpha therapeutics. They see targeted alpha therapeutics as the next generation of radiation therapy. At Fusion, they are pushing the boundaries of science to create innovative cancer treatments. They believe that targeted alpha therapeutics represent the evolution of radiopharmaceuticals which holds great promise to improve the lives of patients with cancer.